|
|
|
|
| LEADER |
01000caa a2200265 4500 |
| 001 |
OLC1988927714 |
| 003 |
DE-627 |
| 005 |
20230513105739.0 |
| 007 |
tu |
| 008 |
170207s2017 xx ||||| 00| ||eng c |
| 024 |
7 |
|
|a 10.1111/apt.13940
|2 doi
|
| 028 |
5 |
2 |
|a PQ20170206
|
| 035 |
|
|
|a (DE-627)OLC1988927714
|
| 035 |
|
|
|a (DE-599)GBVOLC1988927714
|
| 035 |
|
|
|a (PRQ)crossref_primary_10_1111_apt_139400
|
| 035 |
|
|
|a (KEY)0157873120170000000000000000impactofcoexistingimmunemediatedonphenotypeandoutc
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
4 |
|a 610
|q DE-600
|
| 084 |
|
|
|a 44.87
|2 bkl
|
| 084 |
|
|
|a 44.38
|2 bkl
|
| 100 |
1 |
|
|a Conway, G
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The impact of co-existing immune-mediated on phenotype and outcomes in inflammatory bowel diseases
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 700 |
1 |
|
|a Velonias, G
|4 oth
|
| 700 |
1 |
|
|a Andrews, E
|4 oth
|
| 700 |
1 |
|
|a Garber, J. J
|4 oth
|
| 700 |
1 |
|
|a Yajnik, V
|4 oth
|
| 700 |
1 |
|
|a Ananthakrishnan, A. N
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|t Alimentary pharmacology & therapeutics
|d Oxford : Wiley-Blackwell, 1987
|g (2017)
|w (DE-627)130433233
|w (DE-600)639012-2
|w (DE-576)028460936
|x 0269-2813
|7 nnns
|
| 773 |
1 |
8 |
|g year:2017
|
| 856 |
4 |
1 |
|u http://dx.doi.org/10.1111/apt.13940
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_OLC
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a SSG-OLC-DE-84
|
| 912 |
|
|
|a GBV_ILN_4012
|
| 912 |
|
|
|a GBV_ILN_4219
|
| 936 |
b |
k |
|a 44.87
|q AVZ
|
| 936 |
b |
k |
|a 44.38
|q AVZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2017
|
